- Aptevo Therapeutics filed a prospectus supplement under its ATM agreement with Roth Capital Partners.
- The update enables sales of common stock up to an aggregate offering price of $2,309,834.
- Capital raising introduces equity dilution risk for existing shareholders.
?? Negative AI Sentiment (-3.5 / 10)